Achillion Presents Mixed Trial Results – May, Hep C “Awareness Month”

By Mitchell Young

New Haven: Achillion Pharmaceuticals [Nasdaq: ACHN] presented data on its three drug combination to treat Hepatitis C, at The International Liver Congress in Amsterdam in late April, just a week before the national kick-off of Hep C Awareness Month.

Jansen is financially responsible for all clinical trials and they initiated the Phase II clinical trial, last May of 300 participants of the drug combination, simeprevir, odalasvir and AL-335.

Jansen previously developed simeprevir and odalasvir, but required Achilion’s A-335 to achieve the effectiveness needed to cure Hep C.

The clinical results presented could be described as really good and really not so good....
 Continue reading

Watch Advances in Chronic Hepatitis C: Management and Treatment/Independent Review of the 51st Annual EASL

 

Happy Friday everyone, if you have the time check out this recently released Internet symposium over at ViralEd. The program will feature real-world data on current HCV therapies presented at The International Liver Congress this month.

 

The Advances in Chronic Hepatitis C: Management and Treatment

Independent Review of the 51st Annual EASL

 

Internet Symposium: EASL 2016 Review 

The review and discussion will focus on HCV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations; therapies in development; epidemiology; and diagnosis and clinical management of specific patient populations, including HCV/HIV co-infected and cirrhotic patients.

 

LAUNCH ON-DEMAND PROGRAM